These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22733022)

  • 1. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
    Karp JE; Garrett-Mayer E; Estey EH; Rudek MA; Smith BD; Greer JM; Drye DM; Mackey K; Dorcy KS; Gore SD; Levis MJ; McDevitt MA; Carraway HE; Pratz KW; Gladstone DE; Showel MM; Othus M; Doyle LA; Wright JJ; Pagel JM
    Haematologica; 2012 Nov; 97(11):1736-42. PubMed ID: 22733022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
    Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
    Karp JE; Blackford A; Smith BD; Alino K; Seung AH; Bolaños-Meade J; Greer JM; Carraway HE; Gore SD; Jones RJ; Levis MJ; McDevitt MA; Doyle LA; Wright JJ
    Leuk Res; 2010 Jul; 34(7):877-82. PubMed ID: 19962759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
    Zeidner JF; Foster MC; Blackford AL; Litzow MR; Morris LE; Strickland SA; Lancet JE; Bose P; Levy MY; Tibes R; Gojo I; Gocke CD; Rosner GL; Little RF; Wright JJ; Doyle LA; Smith BD; Karp JE
    Haematologica; 2015 Sep; 100(9):1172-9. PubMed ID: 26022709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
    Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; Joseph B; Carraway H; McDevitt MA; Bagain L; Mackey K; Briel J; Doyle LA; Wright JJ; Rudek MA
    Blood; 2011 Mar; 117(12):3302-10. PubMed ID: 21239698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?
    van der Jagt RH
    Leuk Res; 2010 Jul; 34(7):856-7. PubMed ID: 20378170
    [No Abstract]   [Full Text] [Related]  

  • 7. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
    LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
    Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Bolaños-Meade J; Guo C; Gojo I; Karp JE
    Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
    Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
    Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
    Kalaycio M; Pohlman B; Elson P; Lichtin A; Hussein M; Tripp B; Andresen S
    Am J Clin Oncol; 2001 Feb; 24(1):58-63. PubMed ID: 11232951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.
    Liang R; Chan TK; Chu YC; Chan J; Chan CH; Chiu E; Lie A; Kwong YL; Yeung YM; Chan LC
    Anticancer Drugs; 1995 Apr; 6(2):224-8. PubMed ID: 7795271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
    Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
    J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
    Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
    Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
    Walters RS; Kantarjian HM; Keating MJ; Plunkett WK; Estey EH; Andersson B; Beran M; McCredie KB; Freireich EJ
    Cancer; 1988 Aug; 62(4):677-82. PubMed ID: 3165047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.